Tag: MarketWatch

Posted on

AstraZeneca: Asthma drug trial results positive – MarketWatch


Reuters UK

AstraZeneca: Asthma drug trial results positive
MarketWatch
LONDON–AstraZeneca PLC (AZN.LN) said Tuesday its potential new medicine benralizumab showed positive results in a Phase III trial for asthma treatment. The treatment "was well tolerated and achieved the primary endpoint in two pivotal Phase III …
AstraZeneca boosted by good results for biotech asthma drugReuters UK
Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe AsthmaNasdaq
TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial ResultsLondon South East (registration) (blog)

all 4 news articles »

View full post on asthma – Google News

Posted on

Glaxo’s asthma drug Nucala gets Japanese approval – MarketWatch


Lung Disease News

Glaxo's asthma drug Nucala gets Japanese approval
MarketWatch
The Japanese Ministry of Health, Labour and Welfare granted approval for the drug "as a treatment for bronchial asthma in patients with refractory asthma whose symptoms are inadequately controlled with standard treatment," Glaxo said Tuesday.
FDA Approves Teva's Asthma Drug Cinqair as Add-on TreatmentLung Disease News
GSK: Nucala Receives Approval In Japan For Treatment Of Bronchial AsthmaRTT News
Nucala and Cinqair for the Treatment of Severe AsthmaAbout – News & Issues

all 4 news articles »

View full post on asthma – Google News

Posted on

Merck’s stock falls after disclosing government probe into asthma drug pricing – MarketWatch

Merck's stock falls after disclosing government probe into asthma drug pricing
MarketWatch
Merck & Co. Inc.'s stock dropped 1.5% in midday trade Friday, after the drug maker disclosed in a filing late Thursday that it had received a civil investigative demand from the U.S. Attorney's office. The demand requests information related to the …

View full post on asthma – Google News

Posted on

Glaxo asthma drug clears key hurdle in Europe – MarketWatch


Yahoo News

Glaxo asthma drug clears key hurdle in Europe
MarketWatch
LONDON–GlaxoSmithKline PLC's [GSK.LN] new severe-asthma medicine has received a positive opinion from the scientific committee of the European Medicines Agency for use in adults, clearing a key hurdle towards gaining marketing approval in Europe.
EU regulator backs approval for GSK injectable asthma drugYahoo News
GlaxoSmithKline plc (ADR) To Lead Asthma MarketBidness ETC
GlaxoSmithKline's asthma injection heads for EU approvalFierceBiotech

all 24 news articles »

View full post on asthma – Google News

Posted on

Despite Generic Erosion of Current Market Leaders, the Asthma Market Will … – MarketWatch

Despite Generic Erosion of Current Market Leaders, the Asthma Market Will …
MarketWatch
BURLINGTON, Mass., Sept. 22, 2015 /PRNewswire/ — Decision Resources Group finds that the market for asthma will remain relatively flat, increasing slightly from $15.9 billion in 2014 to $16.2 billion in 2024 across the seven major markets (the United …

View full post on asthma – Google News

Posted on

Teva Announces European Medicines Agency (EMA) Confirms Successful Validation … – MarketWatch

Teva Announces European Medicines Agency (EMA) Confirms Successful Validation …
MarketWatch
“Uncontrolled asthma remains a serious challenge for patients and healthcare professionals despite the availability of standard of care treatment,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical …

and more »

View full post on asthma – Google News

Posted on

Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy … – MarketWatch

Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy …
MarketWatch
Mylan President Rajiv Malik said, "Mylan is excited to be the first company to offer adult asthma patients in the UK the generic version of Seretide Evohaler, delivering on our mission to increase access to high quality medicine. Sirdupla represents a …

and more »

View full post on asthma – Google News

Posted on

Glaxo submits new asthma drug application in Japan – MarketWatch

Glaxo submits new asthma drug application in Japan
MarketWatch
LONDON–Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said Friday it has submitted a new drug application to the Japanese health ministry for mepolizumab, a drug used for treating a type of severe asthma. The application for mepolizumab has …
Glaxo Submits Japan Application For Mepolizumab In Eosinophilic AsthmaLondon South East

all 2 news articles »

View full post on asthma – Google News